Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN D BECKES

Allopathic & Osteopathic Physicians Hospitalist

NPI
1639118912
CMS profile
836653
Location
NATIONAL CITY, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$124.99

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $124.99 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Biosense Webster, Inc. $124.99 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN D BECKES

NPI 1639118912 · CMS profile ID 836653

Allopathic & Osteopathic Physicians / Hospitalist

NATIONAL CITY, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639118912?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN D BECKES, NPI 1639118912, CMS profile ID 836653. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639118912?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JOHN D BECKES, NPI 1639118912, CMS profile ID 836653. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639118912?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JOHN D BECKES, NPI 1639118912, CMS profile ID 836653, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1639118912?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $124.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biosense Webster, Inc. $124.9909/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648652979 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $124.99 1
PY2023 $3,065.23 9
PY2024 $570.95 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,605,177.75 703
PY2024 Recipient $1,613.98 3
PY2024 Principal investigator $3,238,637.82 219
PY2023 Recipient $1,016.73 1
PY2023 Principal investigator $5,966,992.99 5,656
PY2022 Recipient $456.00 1
PY2022 Principal investigator $3,684,980.58 3,955

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

703 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ipsen Innovation $2,718.90 12/30/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301297
Principal investigator 1 Ipsen Innovation $135.00 12/30/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301441
Principal investigator 1 Ipsen Innovation $1,906.20 12/30/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301503
Principal investigator 1 Ipsen Innovation $1,053.00 12/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301093
Principal investigator 1 Ipsen Innovation $600.00 12/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301101
Principal investigator 1 Ipsen Innovation $2,718.90 12/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301403
Principal investigator 1 Ipsen Innovation $1,332.45 12/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301437
Principal investigator 1 Ipsen Innovation $864.00 12/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301451
Principal investigator 1 Ipsen Innovation $731.70 12/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301469
Principal investigator 1 Amgen Inc. $800.00 12/24/2025 Non-covered Recipient Entity
ALLIANCE CLINICAL LLC 310 CLINICAL RESEARCH LLC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246638979
Principal investigator 1 Ipsen Innovation $135.00 12/24/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300969
Principal investigator 1 Ipsen Innovation $135.00 12/24/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301299
Principal investigator 1 Ipsen Innovation $135.00 12/24/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301409
Principal investigator 1 Ipsen Innovation $135.00 12/24/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301417
Principal investigator 1 Ipsen Innovation $135.00 12/24/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301419
Principal investigator 1 Ipsen Innovation $135.00 12/24/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301439
Principal investigator 1 Ipsen Innovation $135.00 12/24/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301465
Principal investigator 1 Ipsen Innovation $135.00 12/24/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301485
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300947
Principal investigator 1 Ipsen Innovation $81.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300949
Principal investigator 1 Ipsen Innovation $67.50 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300951
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300955
Principal investigator 1 Ipsen Innovation $42.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300957
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300959
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300961
Principal investigator 1 Ipsen Innovation $56.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300963
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300965
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300967
Principal investigator 1 Ipsen Innovation $558.90 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300971
Principal investigator 1 Ipsen Innovation $59.40 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300973
Principal investigator 1 Ipsen Innovation $42.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300977
Principal investigator 1 Ipsen Innovation $67.50 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301017
Principal investigator 1 Ipsen Innovation $842.40 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301019
Principal investigator 1 Ipsen Innovation $59.40 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301021
Principal investigator 1 Ipsen Innovation $1,016.55 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301023
Principal investigator 1 Ipsen Innovation $81.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301025
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301027
Principal investigator 1 Ipsen Innovation $270.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301029
Principal investigator 1 Ipsen Innovation $2,219.40 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301031
Principal investigator 1 Ipsen Innovation $14.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301035
Principal investigator 1 Ipsen Innovation $59.40 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301037
Principal investigator 1 Ipsen Innovation $67.50 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301039
Principal investigator 1 Ipsen Innovation $59.40 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301041
Principal investigator 1 Ipsen Innovation $56.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301043
Principal investigator 1 Ipsen Innovation $600.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301045
Principal investigator 1 Ipsen Innovation $84.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301047
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301091
Principal investigator 1 Ipsen Innovation $84.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301097
Principal investigator 1 Ipsen Innovation $56.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301099
Principal investigator 1 Ipsen Innovation $42.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301103
Principal investigator 1 Ipsen Innovation $67.50 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301105
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301107
Principal investigator 1 Ipsen Innovation $81.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301109
Principal investigator 1 Ipsen Innovation $84.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301111
Principal investigator 1 Ipsen Innovation $56.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301113
Principal investigator 1 Ipsen Innovation $56.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301115
Principal investigator 1 Ipsen Innovation $56.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301119
Principal investigator 1 Ipsen Innovation $67.50 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301121
Principal investigator 1 Ipsen Innovation $84.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301267
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301269
Principal investigator 1 Ipsen Innovation $59.40 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301271
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301273
Principal investigator 1 Ipsen Innovation $2,718.90 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301275
Principal investigator 1 Ipsen Innovation $67.50 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301277
Principal investigator 1 Ipsen Innovation $81.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301279
Principal investigator 1 Ipsen Innovation $59.40 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301283
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301285
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301287
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301289
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301291
Principal investigator 1 Ipsen Innovation $67.50 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301293
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301295
Principal investigator 1 Ipsen Innovation $14.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301301
Principal investigator 1 Ipsen Innovation $84.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301305
Principal investigator 1 Ipsen Innovation $67.50 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301405
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301411
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301413
Principal investigator 1 Ipsen Innovation $84.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301415
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301423
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301425
Principal investigator 1 Ipsen Innovation $14.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301427
Principal investigator 1 Ipsen Innovation $70.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301429
Principal investigator 1 Ipsen Innovation $59.40 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301431
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301433
Principal investigator 1 Ipsen Innovation $67.50 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301435
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301443
Principal investigator 1 Ipsen Innovation $329.40 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301445
Principal investigator 1 Ipsen Innovation $67.50 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301447
Principal investigator 1 Ipsen Innovation $14.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301449
Principal investigator 1 Ipsen Innovation $67.50 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301453
Principal investigator 1 Ipsen Innovation $14.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301455
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301459
Principal investigator 1 Ipsen Innovation $67.50 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301461
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301463
Principal investigator 1 Ipsen Innovation $81.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301467
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301471
Principal investigator 1 Ipsen Innovation $84.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301473
Principal investigator 1 Ipsen Innovation $67.50 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301475
Principal investigator 1 Ipsen Innovation $56.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301477
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301481
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301483
Principal investigator 1 Ipsen Innovation $98.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301487
Principal investigator 1 Ipsen Innovation $580.50 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301489
Principal investigator 1 Ipsen Innovation $56.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301491
Principal investigator 1 Ipsen Innovation $56.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301493
Principal investigator 1 Ipsen Innovation $67.50 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301495
Principal investigator 1 Ipsen Innovation $42.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301497
Principal investigator 1 Ipsen Innovation $2,219.40 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301499
Principal investigator 1 Ipsen Innovation $59.40 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301505
Principal investigator 1 Ipsen Innovation $14.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301507
Principal investigator 1 Ipsen Innovation $2,111.40 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301509
Principal investigator 1 Ipsen Innovation $135.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301511
Principal investigator 1 Ipsen Innovation $1,760.40 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301513
Principal investigator 1 Ipsen Innovation $56.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301515
Principal investigator 1 Ipsen Innovation $1,760.40 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301517
Principal investigator 1 Ipsen Innovation $14.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301519
Principal investigator 1 Ipsen Innovation $270.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184301521
Principal investigator 1 PFIZER INC. $20.00 12/19/2025 Non-covered Recipient Entity
Alliance Clinical Holdings LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228738882
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $901.74 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279048
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,421.00 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279050
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,011.60 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279052
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $672.00 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279054
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $450.00 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279056
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,813.00 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279058
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $714.00 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279060
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $485.80 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279062
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $875.00 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279064
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279066
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $420.00 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279068
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $49.00 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279070
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $379.80 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279072
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $714.00 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279074
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $168.00 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279076
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,584.40 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279078
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,850.00 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279080
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,943.00 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279082
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,996.00 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279084
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,375.00 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279086
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $392.00 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279088
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $168.00 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279090
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,150.00 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279092
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,998.00 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279094
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $147.00 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279096
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $714.00 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279098
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,216.20 12/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279100
Principal investigator 1 Boehringer Ingelheim International GmbH $3,394.60 12/18/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743315
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 12/17/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220743251
Principal investigator 1 Boehringer Ingelheim International GmbH $5,766.60 12/17/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743305
Principal investigator 1 Boehringer Ingelheim International GmbH $5,429.60 12/17/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743307
Principal investigator 1 Boehringer Ingelheim International GmbH $4,403.10 12/17/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743309
Principal investigator 1 Boehringer Ingelheim International GmbH $5,463.35 12/17/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743311
Principal investigator 1 Boehringer Ingelheim International GmbH $3,111.90 12/17/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743313
Principal investigator 1 Boehringer Ingelheim International GmbH $5,550.00 12/17/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743317
Principal investigator 1 Boehringer Ingelheim International GmbH $5,546.70 12/17/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743319
Principal investigator 1 Boehringer Ingelheim International GmbH $5,734.20 12/17/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743321
Principal investigator 1 Boehringer Ingelheim International GmbH $2,914.55 12/17/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743323
Principal investigator 1 Boehringer Ingelheim International GmbH $1,795.50 12/17/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743325
Principal investigator 1 Boehringer Ingelheim International GmbH $2,018.25 12/17/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743327
Principal investigator 1 Boehringer Ingelheim International GmbH $5,605.10 12/17/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743329
Principal investigator 1 Boehringer Ingelheim International GmbH $5,610.00 12/17/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743331
Principal investigator 1 Boehringer Ingelheim International GmbH $5,270.45 12/17/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743333
Principal investigator 1 Boehringer Ingelheim International GmbH $3,570.75 12/17/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743337
Principal investigator 1 Boehringer Ingelheim International GmbH $5,558.70 12/17/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743339
Principal investigator 1 Boehringer Ingelheim International GmbH $5,738.25 12/17/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743341
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 12/17/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743355
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 12/17/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743357
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 12/17/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220743387
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 12/17/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220743389
Principal investigator 1 Novartis Pharmaceuticals Corporation $454.30 12/15/2025 Non-covered Recipient Entity
ALLIANCE CLINICAL NETWORK
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190313727
Principal investigator 1 Ipsen Innovation $360.00 12/12/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184301407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39,152.54 12/11/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274636
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,134.25 12/09/2025 Non-covered Recipient Entity
Alliance Clinical Holdings, LLC Acclaim Clinical Research, LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220815089
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 12/09/2025 Non-covered Recipient Entity
Alliance Clinical Holdings, LLC Acclaim Clinical Research, LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220815091
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 12/04/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220997828
Principal investigator 1 Boehringer Ingelheim International GmbH $4,123.60 12/03/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743335
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 12/01/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220743377
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 12/01/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220743379
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 12/01/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220743381
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220743383
Principal investigator 1 PFIZER INC. $113.00 11/29/2025 Non-covered Recipient Entity
Alliance Clinical Holdings LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228727049
Principal investigator 1 Ipsen Innovation $3,164.40 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300247
Principal investigator 1 Ipsen Innovation $2,439.45 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300251
Principal investigator 1 Ipsen Innovation $71.55 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300253
Principal investigator 1 Ipsen Innovation $966.60 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300257
Principal investigator 1 Ipsen Innovation $71.55 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300263
Principal investigator 1 Ipsen Innovation $966.60 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300265
Principal investigator 1 Ipsen Innovation $71.55 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300267
Principal investigator 1 Ipsen Innovation $2,439.45 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300273
Principal investigator 1 Ipsen Innovation $1,111.05 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300307
Principal investigator 1 Ipsen Innovation $966.60 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300311
Principal investigator 1 Ipsen Innovation $966.60 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300313
Principal investigator 1 Ipsen Innovation $3,164.40 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300315
Principal investigator 1 Ipsen Innovation $1,111.05 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300321
Principal investigator 1 Ipsen Innovation $966.60 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300323
Principal investigator 1 Ipsen Innovation $3,164.40 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300329
Principal investigator 1 Ipsen Innovation $71.55 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300331
Principal investigator 1 Ipsen Innovation $3,164.40 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300335
Principal investigator 1 Ipsen Innovation $2,439.45 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300337
Principal investigator 1 Ipsen Innovation $2,439.45 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300435
Principal investigator 1 Ipsen Innovation $966.60 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300437
Principal investigator 1 Ipsen Innovation $1,111.05 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300451
Principal investigator 1 Ipsen Innovation $2,439.45 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300463
Principal investigator 1 Ipsen Innovation $966.60 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300467
Principal investigator 1 Ipsen Innovation $966.60 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300481
Principal investigator 1 Ipsen Innovation $2,439.45 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300483
Principal investigator 1 Ipsen Innovation $2,439.45 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300487
Principal investigator 1 Ipsen Innovation $3,164.40 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300609
Principal investigator 1 Ipsen Innovation $1,111.05 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300619
Principal investigator 1 Ipsen Innovation $3,164.40 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300621
Principal investigator 1 Ipsen Innovation $2,439.45 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300623
Principal investigator 1 Ipsen Innovation $966.60 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300629
Principal investigator 1 Ipsen Innovation $3,164.40 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300867
Principal investigator 1 Ipsen Innovation $2,439.45 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300869
Principal investigator 1 Ipsen Innovation $1,111.05 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300877
Principal investigator 1 Ipsen Innovation $966.60 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300881
Principal investigator 1 Ipsen Innovation $2,439.45 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300885
Principal investigator 1 Ipsen Innovation $966.60 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300893
Principal investigator 1 Ipsen Innovation $71.55 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300907
Principal investigator 1 Ipsen Innovation $966.60 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300911
Principal investigator 1 Ipsen Innovation $966.60 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300913
Principal investigator 1 Ipsen Innovation $71.55 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300915
Principal investigator 1 Ipsen Innovation $1,111.05 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300917
Principal investigator 1 Ipsen Innovation $1,111.05 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300919
Principal investigator 1 Ipsen Innovation $71.55 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300929
Principal investigator 1 Ipsen Innovation $1,111.05 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300931
Principal investigator 1 Ipsen Innovation $2,439.45 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300933
Principal investigator 1 Ipsen Innovation $2,439.45 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300935
Principal investigator 1 Ipsen Innovation $966.60 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300937
Principal investigator 1 Ipsen Innovation $1,763.10 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300941
Principal investigator 1 Ipsen Innovation $3,164.40 11/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300943
Principal investigator 1 Ipsen Innovation $135.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300245
Principal investigator 1 Ipsen Innovation $135.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300269
Principal investigator 1 Ipsen Innovation $135.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300271
Principal investigator 1 Ipsen Innovation $135.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300275
Principal investigator 1 Ipsen Innovation $135.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300317
Principal investigator 1 Ipsen Innovation $135.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300439
Principal investigator 1 Ipsen Innovation $135.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300447
Principal investigator 1 Ipsen Innovation $135.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300449
Principal investigator 1 Ipsen Innovation $42.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300453
Principal investigator 1 Ipsen Innovation $67.50 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300455
Principal investigator 1 Ipsen Innovation $540.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300459
Principal investigator 1 Ipsen Innovation $135.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300461
Principal investigator 1 Ipsen Innovation $135.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300469
Principal investigator 1 Ipsen Innovation $135.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300471
Principal investigator 1 Ipsen Innovation $67.50 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300477
Principal investigator 1 Ipsen Innovation $135.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300617
Principal investigator 1 Ipsen Innovation $67.50 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300845
Principal investigator 1 Ipsen Innovation $135.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300847
Principal investigator 1 Ipsen Innovation $135.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300863
Principal investigator 1 Ipsen Innovation $84.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300865
Principal investigator 1 Ipsen Innovation $135.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300875
Principal investigator 1 Ipsen Innovation $135.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300883
Principal investigator 1 Ipsen Innovation $135.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300887
Principal investigator 1 Ipsen Innovation $56.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300899
Principal investigator 1 Ipsen Innovation $42.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300903
Principal investigator 1 Ipsen Innovation $28.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300905
Principal investigator 1 Ipsen Innovation $84.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300909
Principal investigator 1 Ipsen Innovation $84.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300921
Principal investigator 1 Ipsen Innovation $135.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300925
Principal investigator 1 Ipsen Innovation $56.00 11/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300927
Principal investigator 1 Ipsen Innovation $81.00 11/26/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300249
Principal investigator 1 Ipsen Innovation $2,111.40 11/26/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300333
Principal investigator 1 Ipsen Innovation $59.40 11/26/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300441
Principal investigator 1 Ipsen Innovation $2,475.90 11/26/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300457
Principal investigator 1 Ipsen Innovation $81.00 11/26/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300611
Principal investigator 1 Ipsen Innovation $59.40 11/26/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300615
Principal investigator 1 Ipsen Innovation $1,467.45 11/26/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300625
Principal investigator 1 Ipsen Innovation $2,556.90 11/26/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300855
Principal investigator 1 Ipsen Innovation $98.00 11/26/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300859
Principal investigator 1 Ipsen Innovation $56.00 11/26/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300873
Principal investigator 1 Ipsen Innovation $81.00 11/26/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300889
Principal investigator 1 Ipsen Innovation $14.00 11/26/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300901
Principal investigator 1 Amgen Inc. $1,912.08 11/25/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246641167
Principal investigator 1 Ipsen Innovation $150.00 11/25/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291664
Principal investigator 1 Ipsen Innovation $270.00 11/25/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291666
Principal investigator 1 Ipsen Innovation $90.00 11/25/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291668
Principal investigator 1 Ipsen Innovation $3,164.40 11/24/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300259
Principal investigator 1 Ipsen Innovation $3,164.40 11/24/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300465
Principal investigator 1 Ipsen Innovation $3,164.40 11/24/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300607
Principal investigator 1 Ipsen Innovation $3,164.40 11/24/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300871
Principal investigator 1 Genentech, Inc. $3,792.38 11/20/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211601151
Principal investigator 1 Boehringer Ingelheim International GmbH $839.50 11/19/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743351
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 11/19/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743353
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 11/19/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220743385
Principal investigator 1 Ipsen Innovation $3,164.40 11/17/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300861
Principal investigator 1 Ipsen Innovation $3,164.40 11/17/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 11/14/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261349
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 11/11/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220997826
Principal investigator 1 Ipsen Innovation $600.00 11/07/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,813.00 11/07/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184259009
Principal investigator 1 Ipsen Innovation $98.00 11/05/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300255
Principal investigator 1 Ipsen Innovation $135.00 11/05/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300261
Principal investigator 1 Ipsen Innovation $232.20 11/05/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300309
Principal investigator 1 Ipsen Innovation $81.00 11/05/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300319
Principal investigator 1 Ipsen Innovation $135.00 11/05/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300325
Principal investigator 1 Ipsen Innovation $135.00 11/05/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300327
Principal investigator 1 Ipsen Innovation $67.50 11/05/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300443
Principal investigator 1 Ipsen Innovation $135.00 11/05/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300445
Principal investigator 1 Ipsen Innovation $135.00 11/05/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300473
Principal investigator 1 Ipsen Innovation $81.00 11/05/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300475
Principal investigator 1 Ipsen Innovation $67.50 11/05/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300479
Principal investigator 1 Ipsen Innovation $135.00 11/05/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300485
Principal investigator 1 Ipsen Innovation $135.00 11/05/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300627
Principal investigator 1 Ipsen Innovation $135.00 11/05/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300849
Principal investigator 1 Ipsen Innovation $59.40 11/05/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300851
Principal investigator 1 Ipsen Innovation $135.00 11/05/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300853
Principal investigator 1 Ipsen Innovation $135.00 11/05/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300857
Principal investigator 1 Ipsen Innovation $56.00 11/05/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300879
Principal investigator 1 Ipsen Innovation $135.00 11/05/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300891
Principal investigator 1 Ipsen Innovation $135.00 11/05/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300897
Principal investigator 1 Ipsen Innovation $67.50 11/05/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300923
Principal investigator 1 Ipsen Innovation $84.00 11/05/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300939
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220743375
Principal investigator 1 PFIZER INC. $1,444.10 10/31/2025 Non-covered Recipient Entity
Alliance Clinical Holdings LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228729863
Principal investigator 1 Ipsen Innovation $600.00 10/30/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300181
Principal investigator 1 Ardelyx, Inc. $15,000.00 10/29/2025 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH LLC
A 26-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Chronic Idiopathic Constipation (CIC) in Adults No dispute reported 06/30/2026 1247838772
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $761.30 10/29/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184253618
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 10/27/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220743249
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 10/27/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743343
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 10/27/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743345
Principal investigator 1 Boehringer Ingelheim International GmbH $474.50 10/27/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743347
Principal investigator 1 Boehringer Ingelheim International GmbH $2.00 10/27/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743349
Principal investigator 1 Ipsen Innovation $1,111.05 10/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300177
Principal investigator 1 Ipsen Innovation $71.55 10/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300187
Principal investigator 1 Ipsen Innovation $71.55 10/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300189
Principal investigator 1 Ipsen Innovation $71.55 10/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300195
Principal investigator 1 Ipsen Innovation $71.55 10/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300197
Principal investigator 1 Ipsen Innovation $71.55 10/27/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184300201
Principal investigator 1 Ipsen Innovation $180.00 10/23/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291654
Principal investigator 1 Ipsen Innovation $750.00 10/23/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291656
Principal investigator 1 Ipsen Innovation $450.00 10/23/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291658
Principal investigator 1 Ipsen Innovation $270.00 10/17/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291652
Principal investigator 1 Ipsen Innovation $150.00 10/17/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291660
Principal investigator 1 Ipsen Innovation $90.00 10/17/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291662
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39,445.14 10/16/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250687
Principal investigator 1 Ipsen Innovation $205.00 10/15/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300175
Principal investigator 1 Ipsen Innovation $135.00 10/15/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300179
Principal investigator 1 Ipsen Innovation $135.00 10/15/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300183
Principal investigator 1 Ipsen Innovation $135.00 10/15/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300185
Principal investigator 1 Ipsen Innovation $258.50 10/15/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300191
Principal investigator 1 Ipsen Innovation $70.00 10/15/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300193
Principal investigator 1 Ipsen Innovation $81.50 10/15/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300199
Principal investigator 1 Ipsen Innovation $135.00 10/15/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300203
Principal investigator 1 Ipsen Innovation $135.00 10/15/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300205
Principal investigator 1 Ipsen Innovation $135.00 10/15/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300207
Principal investigator 1 Ipsen Innovation $135.00 10/15/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300209
Principal investigator 1 Ipsen Innovation $270.00 10/15/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184300211
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $4,727.00 10/15/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068257
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,260.00 10/15/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068259
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $25,415.25 10/15/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068263
Principal investigator 1 PFIZER INC. $657.30 10/15/2025 Non-covered Recipient Entity
Alliance Clinical Holdings LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228741390
Principal investigator 1 AstraZeneca Pharmaceuticals LP $20,100.00 10/10/2025 Non-covered Recipient Entity
ALLIANCE CLINICAL HOLDINGS
a phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure No dispute reported 06/30/2026 1185539157
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $7,182.00 10/10/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068251
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,694.42 10/09/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184248972
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,662.61 10/03/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244693
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220743373
Principal investigator 1 Ipsen Innovation $966.60 09/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299487
Principal investigator 1 Ipsen Innovation $1,111.05 09/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299489
Principal investigator 1 Ipsen Innovation $966.60 09/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184299491
Principal investigator 1 Ipsen Innovation $71.55 09/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299493
Principal investigator 1 Ipsen Innovation $71.55 09/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299495
Principal investigator 1 Ipsen Innovation $71.55 09/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299497
Principal investigator 1 Ipsen Innovation $71.55 09/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184299501
Principal investigator 1 Ipsen Innovation $71.55 09/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299503
Principal investigator 1 Ipsen Innovation $3,164.40 09/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299509
Principal investigator 1 Ipsen Innovation $71.55 09/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299519
Principal investigator 1 Ipsen Innovation $2,439.45 09/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299521
Principal investigator 1 Ipsen Innovation $3,164.40 09/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299523
Principal investigator 1 Ipsen Innovation $71.55 09/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299525
Principal investigator 1 Ipsen Innovation $71.55 09/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299529
Principal investigator 1 Ipsen Innovation $2,439.45 09/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184299531
Principal investigator 1 Ipsen Innovation $966.60 09/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184299535
Principal investigator 1 Ipsen Innovation $2,439.45 09/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299539
Principal investigator 1 Ipsen Innovation $71.55 09/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299543
Principal investigator 1 Ipsen Innovation $71.55 09/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299547
Principal investigator 1 Ipsen Innovation $71.55 09/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299549
Principal investigator 1 Ipsen Innovation $966.60 09/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299551
Principal investigator 1 Ipsen Innovation $966.60 09/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299553
Principal investigator 1 Ipsen Innovation $71.55 09/29/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299555
Principal investigator 1 Amgen Inc. $4,330.40 09/23/2025 Non-covered Recipient Entity
ALLIANCE CLINICAL RESEARCH
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246638995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33,143.60 09/23/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241660
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18,450.00 09/23/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241662
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,385.65 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240508
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $49.00 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240510
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,428.00 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240512
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $600.00 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240514
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,712.00 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240516
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $392.00 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240518
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,300.00 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240520
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $666.40 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240522
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.00 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240524
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $357.00 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240526
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $399.00 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240528
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,813.00 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240530
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240532
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240534
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $79.80 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240536
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $79.80 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240538
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $49.00 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240540
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240542
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240544
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240546
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,813.00 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240548
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240550
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $79.80 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240552
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,813.00 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240554
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $49.00 09/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240556
Principal investigator 1 Ipsen Innovation $135.00 09/17/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184299505
Principal investigator 1 Ipsen Innovation $120.15 09/17/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184299515
Principal investigator 1 Ipsen Innovation $135.00 09/17/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184299541
Principal investigator 1 Ipsen Innovation $135.00 09/17/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184299545
Principal investigator 1 Ipsen Innovation $135.00 09/15/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299485
Principal investigator 1 Ipsen Innovation $81.00 09/15/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299507
Principal investigator 1 Ipsen Innovation $135.00 09/15/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299511
Principal investigator 1 Ipsen Innovation $81.00 09/15/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299513
Principal investigator 1 Ipsen Innovation $135.00 09/15/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299517
Principal investigator 1 Ipsen Innovation $135.00 09/15/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299527
Principal investigator 1 Ipsen Innovation $135.00 09/15/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299533
Principal investigator 1 Ipsen Innovation $135.00 09/15/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299537
Principal investigator 1 Ipsen Innovation $120.15 09/12/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184299499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $138,108.53 09/10/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235865
Principal investigator 1 PFIZER INC. $717.30 09/09/2025 Non-covered Recipient Entity
Alliance Clinical Holdings LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228749083
Principal investigator 1 Janssen Research & Development, LLC $732.80 09/08/2025 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175276933
Principal investigator 1 F. Hoffmann-La Roche AG $375.00 09/04/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211600998
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,499.23 09/04/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,500.00 09/04/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,999.20 09/04/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,426.00 09/04/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,600.00 09/04/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235191
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220743367
Principal investigator 1 Ipsen Innovation $71.55 08/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184298909
Principal investigator 1 Ipsen Innovation $2,439.45 08/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184298911
Principal investigator 1 Ipsen Innovation $71.55 08/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184298913
Principal investigator 1 Ipsen Innovation $135.00 08/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184298915
Principal investigator 1 Ipsen Innovation $71.55 08/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184298921
Principal investigator 1 Ipsen Innovation $71.55 08/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184298925
Principal investigator 1 Ipsen Innovation $71.55 08/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184298927
Principal investigator 1 Ipsen Innovation $135.00 08/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184298929
Principal investigator 1 Ipsen Innovation $71.55 08/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184298931
Principal investigator 1 Ipsen Innovation $600.00 08/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184298933
Principal investigator 1 Ipsen Innovation $3,164.40 08/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184298937
Principal investigator 1 Ipsen Innovation $71.55 08/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184298939
Principal investigator 1 Ipsen Innovation $71.55 08/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184298941
Principal investigator 1 Ipsen Innovation $71.55 08/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184298945
Principal investigator 1 Ipsen Innovation $600.00 08/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184298947
Principal investigator 1 Ipsen Innovation $71.55 08/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184298949
Principal investigator 1 Ipsen Innovation $71.55 08/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184298951
Principal investigator 1 Ipsen Innovation $3,164.40 08/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184298953
Principal investigator 1 Ipsen Innovation $71.55 08/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184298955
Principal investigator 1 Ipsen Innovation $2,439.45 08/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184298957
Principal investigator 1 Ipsen Innovation $71.55 08/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184298959
Principal investigator 1 Ipsen Innovation $71.55 08/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184298961
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 08/26/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220743369
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 08/26/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220743371
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,150.00 08/26/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230371
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,450.00 08/26/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230373
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,998.00 08/26/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230375
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,405.44 08/26/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230653
Principal investigator 1 Amgen Inc. $301,213.24 08/23/2025 Non-covered Recipient Entity
ALLIANCE CLINICAL LLC 310 CLINICAL RESEARCH LLC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246638975
Principal investigator 1 Amgen Inc. $76,272.71 08/23/2025 Non-covered Recipient Entity
ALLIANCE CLINICAL LLC 310 CLINICAL RESEARCH LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246638985
Principal investigator 1 Ipsen Innovation $135.00 08/22/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184298917
Principal investigator 1 Ipsen Innovation $135.00 08/22/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184298919
Principal investigator 1 Ipsen Innovation $135.00 08/22/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184298923
Principal investigator 1 Ipsen Innovation $135.00 08/22/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184298935
Principal investigator 1 Ipsen Innovation $135.00 08/22/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184298943
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 08/21/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220997824
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,361.71 08/21/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184229757
Principal investigator 1 Ipsen Innovation $600.00 08/20/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291642
Principal investigator 1 Ipsen Innovation $360.00 08/20/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291644
Principal investigator 1 Ipsen Innovation $600.00 08/20/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291646
Principal investigator 1 Ipsen Innovation $300.00 08/18/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291640
Principal investigator 1 Ipsen Innovation $180.00 08/18/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291648
Principal investigator 1 Ipsen Innovation $300.00 08/18/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291650
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 08/14/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220811036
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,290.58 08/07/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226159
Principal investigator 1 PFIZER INC. $1,425.20 08/05/2025 Non-covered Recipient Entity
Alliance Clinical Holdings LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228766093
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 08/01/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220743359
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 08/01/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220743361
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 08/01/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220743363
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220743365
Principal investigator 1 Amgen Inc. $435.00 07/31/2025 Non-covered Recipient Entity
ALLIANCE CLINICAL RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246638997
Principal investigator 1 Ipsen Innovation $150.00 07/31/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291578
Principal investigator 1 Ipsen Innovation $90.00 07/31/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291580
Principal investigator 1 Ipsen Innovation $450.00 07/31/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291582
Principal investigator 1 Janssen Research & Development, LLC $18,944.00 07/31/2025 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175275397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,650.53 07/31/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184222854
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,878.00 07/31/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184222856
Principal investigator 1 Boehringer Ingelheim International GmbH $52.00 07/30/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743289
Principal investigator 1 Boehringer Ingelheim International GmbH $52.00 07/30/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743291
Principal investigator 1 Boehringer Ingelheim International GmbH $52.00 07/30/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743293
Principal investigator 1 Boehringer Ingelheim International GmbH $450.00 07/30/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743297
Principal investigator 1 Ipsen Innovation $1,800.00 07/30/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291596
Principal investigator 1 Ipsen Innovation $1,250.00 07/30/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291598
Principal investigator 1 Ipsen Innovation $2,500.00 07/30/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291600
Principal investigator 1 Ipsen Innovation $12,000.00 07/30/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291602
Principal investigator 1 Ipsen Innovation $12,000.00 07/30/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291608
Principal investigator 1 Ipsen Innovation $1,800.00 07/30/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291634
Principal investigator 1 Ipsen Innovation $1,250.00 07/30/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291636
Principal investigator 1 Ipsen Innovation $2,500.00 07/30/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291638
Principal investigator 1 Amgen Inc. $8,101.76 07/28/2025 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246638712
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 07/28/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743301
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 07/28/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743303
Principal investigator 1 Ipsen Innovation $71.55 07/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291610
Principal investigator 1 Ipsen Innovation $71.55 07/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291612
Principal investigator 1 Ipsen Innovation $71.55 07/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291614
Principal investigator 1 Ipsen Innovation $71.55 07/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291616
Principal investigator 1 Ipsen Innovation $71.55 07/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291618
Principal investigator 1 Ipsen Innovation $71.55 07/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291620
Principal investigator 1 Ipsen Innovation $71.55 07/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291622
Principal investigator 1 Ipsen Innovation $71.55 07/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291624
Principal investigator 1 Ipsen Innovation $71.55 07/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291626
Principal investigator 1 Ipsen Innovation $71.55 07/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291628
Principal investigator 1 Ipsen Innovation $71.55 07/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291630
Principal investigator 1 Ipsen Innovation $71.55 07/28/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291632
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 07/25/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220811034
Principal investigator 1 Boehringer Ingelheim International GmbH $52.00 07/23/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743295
Principal investigator 1 Ipsen Innovation $180.00 07/23/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291590
Principal investigator 1 Ipsen Innovation $300.00 07/23/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291592
Principal investigator 1 Ipsen Innovation $600.00 07/23/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291594
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,706.55 07/22/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,537.20 07/22/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217805
Principal investigator 1 Janssen Research & Development, LLC $6,250.00 07/17/2025 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175276922
Principal investigator 1 Janssen Research & Development, LLC $3,007.00 07/17/2025 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175277098
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,829.07 07/17/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217086
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 07/16/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743299
Principal investigator 1 Ipsen Innovation $300.00 07/14/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291576
Principal investigator 1 Ipsen Innovation $300.00 07/14/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291604
Principal investigator 1 Ipsen Innovation $180.00 07/14/2025 Non-covered Recipient Entity
Alliance Clinical Network
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291606
Principal investigator 1 Ipsen Innovation $180.00 07/11/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291584
Principal investigator 1 Ipsen Innovation $300.00 07/11/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291586
Principal investigator 1 Ipsen Innovation $300.00 07/11/2025 Non-covered Recipient Entity
Alliance Clinical Network
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291588
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $3,064.70 07/11/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066985
Principal investigator 1 PFIZER INC. $2,063.60 07/11/2025 Non-covered Recipient Entity
Alliance Clinical Holdings LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228763161
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,113.69 07/07/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184213357
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,236.21 07/04/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212879
Principal investigator 1 Janssen Research & Development, LLC $4,736.00 07/01/2025 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175275581
Principal investigator 1 PFIZER INC. $541.00 06/26/2025 Non-covered Recipient Entity
Alliance Clinical Holdings LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228793087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,885.09 06/24/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184210658
Principal investigator 1 Janssen Research & Development, LLC $2,680.00 06/20/2025 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175277226
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,178.54 06/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184209219
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,813.00 06/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184209221
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $714.00 06/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184209223
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,666.00 06/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184209225
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $98.00 06/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184209227
Principal investigator 1 PFIZER INC. $249.00 06/14/2025 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228777966
Principal investigator 1 Amgen Inc. $2,063.57 06/12/2025 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246638714
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,333.46 06/12/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,712.00 06/12/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $147.00 06/12/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 06/12/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $90,654.13 06/05/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204211
Principal investigator 1 Amgen Inc. $19,642.10 06/04/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246641161
Principal investigator 1 PFIZER INC. $1,199.10 05/30/2025 Non-covered Recipient Entity
Alliance Clinical Holdings LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228783396
Principal investigator 1 Genentech, Inc. $14,850.00 05/28/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211601025
Principal investigator 1 Genentech, Inc. $3,492.00 05/28/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211601046
Principal investigator 1 Genentech, Inc. $10,688.00 05/28/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211601079
Principal investigator 1 Genentech, Inc. $14,850.00 05/28/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211601095
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 05/27/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743285
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 05/27/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743287
Principal investigator 1 Genentech, Inc. $1,314.00 05/27/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211601038
Principal investigator 1 Genentech, Inc. $3,492.00 05/27/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211601058
Principal investigator 1 Genentech, Inc. $1,314.00 05/27/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211601071
Principal investigator 1 Genentech, Inc. $10,688.00 05/27/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211601082
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,370.08 05/27/2025 Non-covered Recipient Entity
ALLIANCE CLINICAL NETWORK
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190311539
Principal investigator 1 PFIZER INC. $7,383.25 05/23/2025 Non-covered Recipient Entity
Alliance Clinical Holdings LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228772165
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 05/22/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743281
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 05/22/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,050.00 05/22/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184197605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,691.00 05/22/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184197607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,998.00 05/22/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184197609
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,856.00 05/22/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184197611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,800.00 05/22/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184197613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,504.00 05/22/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184197615
Principal investigator 1 Janssen Research & Development, LLC $335.00 05/20/2025 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175276271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $49.00 05/15/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194643
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,625.00 05/15/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194645
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,154.20 05/15/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194647
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $2,380.00 05/09/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066311
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $3,780.00 05/09/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066313
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $2,268.00 05/09/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066315
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $700.00 05/09/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066317
Principal investigator 1 AstraZeneca Pharmaceuticals LP $47,450.36 05/07/2025 Non-covered Recipient Entity
ALLIANCE CLINICAL HOLDINGS
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure No dispute reported 06/30/2026 1185539191
Principal investigator 1 Janssen Research & Development, LLC $1,170.00 04/28/2025 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175276023
Principal investigator 1 Janssen Research & Development, LLC $990.00 04/28/2025 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175276663
Principal investigator 1 Amgen Inc. $6,119.00 04/24/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) No dispute reported 06/30/2026 1246641175
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 04/23/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220743237
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 04/23/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220743239
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 04/23/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220743241
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 04/23/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220743243
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 04/23/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220743245
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 04/23/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220743247
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 04/23/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743279
Principal investigator 1 PFIZER INC. $52,904.66 04/23/2025 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228800782
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $252.00 04/23/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184188931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $159.60 04/23/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184188933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.00 04/23/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184188955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $408.80 04/23/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184188957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,878.00 04/23/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184188959
Principal investigator 1 Janssen Research & Development, LLC $4,020.20 04/17/2025 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175277219
Principal investigator 1 Janssen Research & Development, LLC $172.00 04/15/2025 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175276103
Principal investigator 1 Janssen Research & Development, LLC $1,680.00 04/15/2025 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175276535
Principal investigator 1 Janssen Research & Development, LLC $200.00 04/15/2025 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175276906
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,278.00 04/08/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184181936
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,620.00 04/04/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068213
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,224.00 04/04/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068215
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $100.00 04/04/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068217
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $340.00 04/04/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068219
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $3,064.70 04/04/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068221
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $729.00 04/04/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068223
Principal investigator 1 Janssen Research & Development, LLC $720.00 04/02/2025 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175276884
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,400.00 04/01/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180822
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $79.80 04/01/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180960
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 04/01/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180962
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,600.00 04/01/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180964
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,504.00 04/01/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180966
Principal investigator 1 Janssen Research & Development, LLC $1,067.80 03/25/2025 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175275373
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,455.98 03/25/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184178838
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $360.00 03/19/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067119
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16,365.65 03/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174546
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,150.00 03/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174548
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,998.00 03/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174550
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,878.00 03/14/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184173976
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,142.00 03/14/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184173978
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,625.00 03/14/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184173980
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,426.00 03/14/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184173982
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $333.20 03/14/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184173984
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,274.00 03/14/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184173986
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,898.18 03/11/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184170862
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $4,279.00 03/07/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066927
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $5,236.00 03/07/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066929
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $6,075.00 03/07/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067099
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,944.00 03/07/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067101
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $500.00 03/05/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066817
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $3,064.70 03/05/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066821
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $5,394.00 03/05/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066921
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $3,808.00 03/05/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,273.72 03/04/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184156708
Principal investigator 1 PFIZER INC. $14,500.00 03/01/2025 Non-covered Recipient Entity
Alliance Clinical Holdings LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228797559
Principal investigator 1 Boehringer Ingelheim International GmbH $2.14 02/26/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743253
Principal investigator 1 Boehringer Ingelheim International GmbH $12.86 02/26/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743255
Principal investigator 1 Boehringer Ingelheim International GmbH $239.89 02/26/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743257
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 02/26/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743259
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 02/26/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743261
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 02/26/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743263
Principal investigator 1 Boehringer Ingelheim International GmbH $21.43 02/26/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743265
Principal investigator 1 Boehringer Ingelheim International GmbH $3.37 02/26/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743267
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $500.00 02/26/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067487
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 02/25/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743269
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 02/25/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743271
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 02/25/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743273
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 02/25/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743275
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 02/25/2025 Non-covered Recipient Entity
Acclaim Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220743277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,987.45 02/25/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184155414
Principal investigator 1 Janssen Research & Development, LLC $3,077.80 02/19/2025 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175275883
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,152.74 02/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154230
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,998.41 02/11/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184152976
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $15,715.00 02/05/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068095
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $220,231.85 02/05/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,622.55 02/05/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184152472
Principal investigator 1 Amgen Inc. $10,121.45 01/30/2025 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246638716
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,648.09 01/29/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149900
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 01/29/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149902
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/29/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149904
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 01/29/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149906
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $79.80 01/29/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149908
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $229.80 01/29/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149910
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,336.40 01/29/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149912
Principal investigator 1 Eli Lilly and Company $69,245.00 01/28/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187879227
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,469.04 01/28/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190309642
Principal investigator 1 Eli Lilly and Company $356.75 01/27/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187883048
Principal investigator 1 Amgen Inc. $2,598.24 01/24/2025 Non-covered Recipient Entity
ALLIANCE CLINICAL RESEARCH
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246639001
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $650.00 01/24/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067449
Principal investigator 1 Janssen Research & Development, LLC $1,675.00 01/21/2025 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175275345
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,593.45 01/21/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149066
Principal investigator 1 Novartis Pharmaceuticals Corporation $44,612.71 01/17/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190310084
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $23,525.04 01/17/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184148131
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,875.00 01/17/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184148133
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,695.00 01/17/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184148135
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,413.00 01/17/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184148137
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,134.00 01/17/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184148139
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $43,512.00 01/17/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184148141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $54,390.00 01/17/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184148143
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $11,165.35 01/14/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067177
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $6,300.00 01/14/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067179
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $100.00 01/14/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067181
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $340.00 01/14/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067439
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $270.00 01/14/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067441
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $324.00 01/14/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067443
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $540.00 01/14/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067445
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $162.00 01/14/2025 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067447
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,526.15 01/14/2025 Non-covered Recipient Entity
ALLIANCE CLINICAL NETWORK
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190311541
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 01/09/2025 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175275381
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,243.66 01/07/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145864
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,619.52 01/07/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145866
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,142.00 01/07/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145868
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,000.00 01/07/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145870
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $226.00 01/07/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145872
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $539.00 01/07/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145874
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $875.00 01/07/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145876
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 01/07/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145878
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 01/07/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145880
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 01/07/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145882
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $49.00 01/07/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145884